Patents by Inventor Ali Bazarbachi

Ali Bazarbachi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
    Patent number: 11077139
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: August 3, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITA DI PERUGIA, AMERICAN UNIVERSITY OF BEIRUT, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Hugues De The, Ali Bazarbachi, Hiba El Hajj, Maria Paula Martelli, Brunangelo Falini
  • METHODS OF A DROSOPHILA MODEL FOR CHRONIC MYELOID LEUKEMIA (CML) TREATMENT
    Publication number: 20200037588
    Abstract: As disclosed herein, the invention relates to a method of screening for a therapeutic for chronic myeloid leukemia. In an aspect, the invention relates to transgenic Drosophila. In an aspect, the invention relates to a Drosophila system for screening compounds treating chronic myeloid leukemia.
    Type: Application
    Filed: August 1, 2019
    Publication date: February 6, 2020
    Inventors: Rihab Nasr, Margret Shirinian, Amani Al-Outa, Ali Bazarbachi, Marwan El-Sabban
  • COMBINATION OF AN ARSENIC COMPOUND AND AT LEAST ONE RETINOID FOR TREATING ACUTE MYELOID LEUKEMIA
    Publication number: 20160317579
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid.
    Type: Application
    Filed: December 30, 2014
    Publication date: November 3, 2016
    Inventors: Hugues De The, Ali Bazarbachi, Hiba El Hajj, Maria Paula Martelli, Brunangelo Falini
  • Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma
    Patent number: 9107893
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: August 18, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), American University of Beirut
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • Methods, Pharmaceutical Compositions and Kits for Use in the Treatment of Adult T-Cell Leukemia/Lymphoma
    Publication number: 20140286901
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Application
    Filed: June 11, 2014
    Publication date: September 25, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma
    Patent number: 8784797
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: July 22, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), American University of Brirut
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • Imidazol[1,2-?]quinoxalines and derivatives for the treatment of cancers
    Patent number: 8378098
    Abstract: Imidazo[1,2-a]quinoxaline compounds for the treatment of cancers as well as pharmaceutical compositions that include these compounds and their uses in therapy.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: February 19, 2013
    Assignees: Universite de Montpellier I, American University of Beirut, Centre Regional de Lutte Contre le Cancer de Montpellier
    Inventors: Carine Deleuze-Masquefa, Georges Moarbess, Pierre-Antoine Bonnet, Frédéric Pinguet, Ali Bazarbachi, Françoise Bressolle
  • METHODS, PHARMACEUTICAL COMPOSITIONS AND KITS FOR USE IN THE TREATMENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA
    Publication number: 20130004459
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Application
    Filed: December 15, 2009
    Publication date: January 3, 2013
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS
    Publication number: 20100249142
    Abstract: Imidazo[1,2-a]quinoxaline compounds for the treatment of cancers as well as pharmaceutical compositions that include these compounds and their uses in therapy.
    Type: Application
    Filed: October 3, 2008
    Publication date: September 30, 2010
    Inventors: Carine Deleuze-Masquefa, Georges Moarbess, Pierre-Antoine Bonnet, Frédéric Pinguet, Ali Bazarbachi, Francoise Bressolle